Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Daiichi Sankyo, Inc. Post grant review
Case Number:
Case Type:
PGR
Status:
Terminated-Adverse Judgment
Petitioner:
Daiichi Sankyo, Inc.
Patent Owner:
Tech Center:
-
April 08, 2022
PTAB To Review Cancer Antibody IP That Drew $41.8M Verdict
The Patent Trial and Appeal Board has agreed to review a Seagen Inc. antibody patent after the board previously used its discretion to reject two challenges from Daiichi Sankyo Inc. and AstraZeneca while a Texas federal jury on Friday found Daiichi willfully infringed the patent to the tune of $41.8 million.
-
June 25, 2021
PTAB Won't Hear 2 Daiichi PGRs On Cancer Antibody IP
The Patent Trial and Appeal Board said it won't review a Seagen Inc. cancer drug delivery patent being challenged by Daiichi Sankyo Inc. and AstraZeneca, noting that the drugmakers offered few assurances that they won't pursue the same invalidity arguments in parallel district court litigation.